Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness
Authors:
- Margaret C. MinkwitzMMMargaret C. Minkwitz
- Catherine M. BonuccelliCBCatherine M. Bonuccelli
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 82 (5) , 497-503
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Peak Flow LabilityChest, 1997
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposureAllergy, 1995
- Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthmaJournal of Allergy and Clinical Immunology, 1994
- A comparison of fluticasone propionate 200 μg/day with beclomethasone dipropionate 400 μg/day in adult asthmaAllergy, 1994
- A Dose-Ranging Study of Fluticasone Propionate in Adult Patients With Moderate AsthmaChest, 1993
- Peak Expiratory Flow Variability and Bronchial Responsiveness to Methacholine: An Epidemiologic Study in 117 WorkersAmerican Review of Respiratory Disease, 1992
- Measuring compliance with inhaled medication in asthma.Archives of Disease in Childhood, 1992
- A Comparison of the Effects of bid and qid Dosing on Compliance with Inhaled FlunisolideChest, 1992
- The Normal Range of Diurnal Changes in Peak Expiratory Flow Rates: Relationship to Symptoms and Respiratory DiseaseAmerican Review of Respiratory Disease, 1991